Kos Pharmaceuticals, Inc. (Nasdaq:KOSP) announced today results from two studies that represent significant milestones in its research and development activities: data from a study with an optimized Niaspan(R) MF dosage strength and data from the COMPELL (COMParative Effects on Lipid Levels of Niaspan and Statins Versus Other Lipid Therapies) Phase IV efficacy trial.
